Description de l'entreprise
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
Conseil d'administration & Conseil de surveillance
| PDG |
| Dr. Jean-Paul Kress |
| Conseil d'administration |
| Lucinda Crabtree, Ph.D., Tim Demuth, M.D., Ph.D., Barbara Krebs-Pohl, Ph.D., Joe Horvat, Luisa Ciccarelli, Thomas Biegi, Charlotte Lohmann |
| Conseil de surveillance |
| Dr. Marc Cluzel, Dr. George Golumbeski, Krisja Vermeylen, Michael Brosnan, Sharon Curran, Andrew Cheng, M.D., Ph.D. |
Données de l'entreprise
| Nom: |
MorphoSys AG |
| Adresse: |
Semmelweisstr. 7,D-82152 Martinsried/Planegg |
| Téléphone: |
+49-89-89927-0 |
| Fax: |
+49-89-89927-222 |
| Courriel: |
info@morphosys.de
|
| Internet: |
www.morphosys.de |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
70.60% |
| IPO date: |
09/03/1999 |
Relations avec les investisseurs
| Nom: |
Dr. Julia Neugebauer |
| Téléphone IR: |
+49 89 89927 179 |
| IR-Fax: |
- |
| E-mail IR: |
investors@morphosys.com
|
